elea | $4,351,562 | (Mar 13, 2025)
ATLANT 3D | $15,000,000 | (Mar 13, 2025)
Daupler | $15,000,000 | (Mar 13, 2025)
858 Therapeutics
United States
- San Diego, California
- 27/09/2024
- Series B
- $50,000,000
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology.
858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in the fields of epigenetics, single cell genomics, and innate immunity, 858 scientists are dedicated to the company’s mission to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies.
858 is headquartered in the biotech hub of San Diego, CA, and maintains lab operations in both San Diego and New York City, providing proximity to leading investigators and scientific talent on both coasts of the US.
- Industry Biotechnology Research
- Website https://8five8tx.com/
- LinkedIn https://www.linkedin.com/company/858-therapeutics/
Nervonik, Inc. | $13,000,000 | (Mar 13, 2025)
Liminal Experiences, Inc | $5,800,000 | (Mar 13, 2025)
LlamaIndex | $19,000,000 | (Mar 13, 2025)
Odeko | $126,000,000 | (Mar 13, 2025)
QuamCore | $9,000,000 | (Mar 13, 2025)
Carpool Logistics | $12,000,000 | (Mar 13, 2025)